Citi says pills are now 29% of Wegovy prescriptions
The recent Citi report highlights a significant pivot in the obesity market, noting that oral tablets now account for 29% of new prescriptions.
This shift suggests that the "injection-only" era of GLP-1 dominance is facing its first major structural challenge as patients and providers opt for easier-to-administer alternatives.
The weight-loss market has been defined by high-demand injectables like Wegovy and Zepbound. However, the surge to nearly 30% for tablets in such a short period indicates a faster-than-expected adoption of oral versions.
Tablets eliminate "needle phobia" and the logistical hurdle of refrigeration.
Oral formulations are generally cheaper to produce and distribute than complex injector pens.
Analysts suggest that while injections may remain the choice for those needing maximum weight loss, tablets are attracting a new segment of "mildly obese" or overweight patients who might have avoided medical intervention previously.
Citi’s data confirms that 2026 is a "pivotal year." The introduction of oral options is expected to significantly expand the total addressable market (TAM), even if some "cannibalization" of injectable sales occurs.
For investors and patients, the focus is now shifting from efficacy (how much weight is lost) to convenience and adherence (how easy it is to stay on the medication).
The fact that tablets have already captured 29% of the prescription share suggests that the "tablet-first" approach for new patients could soon become the industry standard.